Downregulation of Mad2 and BubR1 increase the malignant potential and nocodazole resistance by compromising spindle assembly checkpoint signaling pathway in cervical carcinogenesis

J Obstet Gynaecol Res. 2019 Dec;45(12):2407-2418. doi: 10.1111/jog.14120. Epub 2019 Sep 15.

Abstract

Aim: To explore the involvement of Mad2 and BubR1 in cervical carcinogenesis.

Methods: The expressions of Mad2 and BubR1 in tissues of high-grade squamous intraepithelial lesions (HSIL), low-grade squamous intraepithelial lesions (LSIL) and chronic cervicitis were analyzed immunohistochemistrily and compared with those of p16INK4A . PEGFP-Mad2 and pEGFP-BubR1 were transfected into SiHa cells to overexpress Mad2 and BubR1 and Si-RNAs to knockdown. Cell viability was measured by cell counting kit-8 (CCK-8) assay. Migration and invasion capabilities were detected by Transwell. Propidium iodide staining with flow cytometry was used for cell cycle analysis and apoptosis was detected using Annexin V/7-AAD staining after nocodazole treatment.

Results: The expression of Mad2 was significantly lower in HSIL than those in chronic cervicitis and LSIL, however, the expression of BubR1 showed no significant differences. To detect HSIL in cervical lesions, Mad2 had a sensitivity of 88.44% and a specificity of 87.23%, Mad2 was less sensitive and more specific than p16INK4a . In SiHa cells, knockdown of Mad2 and BubR1 increased cell growth, reinforced invasion capacity and migration potency, inhibited apoptosis and decreased G2-phase distribution after nocodazole treatment. Oppositely, the overexpression strategies made cells show decreased malignant behaviors, raised apoptosis and increased G2-phase distribution.

Conclusion: Mad2 negativity was specific to identify HSIL immunohistochemistrily. Downregulation of Mad2 and BubR1 increase the malignant behavior and nocodazole resistance of SiHa cells via causing spindle assembly checkpoint defect. This mechanism may contribute to cervical carcinogenesis and resistance to microtubule-targeting drugs.

Keywords: BubR1; Mad2; cervical cancer; high-grade squamous intraepithelial lesion; microtubule-targeting drug.

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Apoptosis / drug effects
  • Cells, Cultured
  • Cervix Uteri / chemistry
  • Cyclin-Dependent Kinase Inhibitor p16 / analysis
  • Down-Regulation
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Mad2 Proteins / analysis
  • Mad2 Proteins / antagonists & inhibitors
  • Mad2 Proteins / physiology*
  • Middle Aged
  • Neoplasm Invasiveness
  • Nocodazole / therapeutic use*
  • Protein Serine-Threonine Kinases / analysis
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Protein Serine-Threonine Kinases / physiology*
  • Signal Transduction / drug effects
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • CDKN2A protein, human
  • Cyclin-Dependent Kinase Inhibitor p16
  • MAD2L1 protein, human
  • Mad2 Proteins
  • BUB1 protein, human
  • Protein Serine-Threonine Kinases
  • Nocodazole